Med. praxi. 2011;8(2):58-63

Anaemia in patients with kidney disease and possibilities of management

doc.MUDr.Romana Ryšavá, CSc.
Klinika nefrologie, 1. LF UK a VFN, Praha

Anaemia is a common comorbidity accompanying chronic kidney disease. It is seen in as many as three-quarters of patients with kidney

failure. It is one of the factors contributing to increased cardiovascular and overall mortality in these patients. The main cause of anaemia

in kidney disease is reduced production of erythropoietin by the failing kidneys. Other factors, such as iron deficiency with impaired

iron utilization, malnutrition and inflammation, also play a role. Currently, it is recommended that the concentration of haemoglobin in

patients with chronic kidney disease be higher than 110 g/l. In addition to iron replacement, several erythropoiesis-stimulating agents

may be used to achieve the desired levels (four original agents containing epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene

glycol-epoetin beta as well as some biosimilars are available). The treatment for anaemia is essential in reducing the mortality

and improving the quality of life of these patients.

Keywords: anaemia, chronic kidney disease, treatment

Published: February 22, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšavá R. Anaemia in patients with kidney disease and possibilities of management. Med. praxi. 2011;8(2):58-63.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eckardt KU. Erytrhropoietin: oxygen-dependent control of erythropoiesis and its failure in rebal disease. Nepheon 1994; 67: 7-23. Go to original source... Go to PubMed...
    2. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2002; 162: 1401-1408. Go to original source... Go to PubMed...
    3. Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004; 15: 347-352. Go to original source... Go to PubMed...
    4. Scortegagna M, Morfia MA, Oktay Y, et al. The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood 2003; 102: 634-640. Go to original source... Go to PubMed...
    5. Jelkmann W. Molecular biology of erythropoietin. Inter Med 2004; 43: 649-659. Go to original source... Go to PubMed...
    6. Verga Falzacappa MV, Muckenthaler MU. Hepcidin: iron-hormone and anti-microbial peptide. Gene 2005; 364: 37-44. Go to original source... Go to PubMed...
    7. Srai SK, Chung B, Marks J, et al. Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int 2010; 78: 660-667. Go to original source... Go to PubMed...
    8. Gilligan D. Adducins: cell biology and erythropoiesis. 3rd Annual C.E.R.A. anaemia academy meeting, 6.8.10.2006, Budapešť. P 19.
    9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in five European countries and associated morbidity and mortality among haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132. Go to original source... Go to PubMed...
    10. Eckardt KU. Managing a fatefull alliance: anaemia and cardivascular outcomes. Nephrol Dial Transplant 2005; 20(Suppl 6): v16-v20. Go to original source... Go to PubMed...
    11. Ritz E. Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant 2005; 20(Suppl. 6): v21-v25. Go to original source... Go to PubMed...
    12. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kideny Disease. AJKD 2006; 47(Suppl 3): S1-S146.
    13. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-ii47. Go to original source...
    14. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass aminy patients ith chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156. Go to original source... Go to PubMed...
    15. Eckardt KU, Macdougall I, Locatelli F, et al. Effects of epoetin beta on left ventricular mass in patients with chronic kidney disease: echocardiographic results from the CREATE study. J Am Soc Nephrol 2005; 16: 37A, THFC 172.
    16. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. Go to original source... Go to PubMed...
    17. Pfeffer MA, Burdmann EA, Chen ChY, et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032. Go to original source... Go to PubMed...
    18. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for reevaluation. N Engl J Med; 362: 189-192.
    19. Alcázar R, Tato A, Garcia F, et al. Would prescription of erythropoiesis stimulating agents in pre-dialysis change after results from TREAT study? Nephrologia 2010; 30: 114-118.
    20. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155. Go to original source... Go to PubMed...
    21. Haselbeck A. C.E.R.A.: knowledge translating into new therapies. 3rd Annual C.E.R.A. anaemia academy meeting, 6.8.10.2006, Budapešť. P 11.
    22. Gouva C, Nikolopoulos P, Ioannidis JPA, et al. Treating anaemia early in renal failure patients slows the decline of renal function; A randomized controlled trial. Kidney Int 2004; 66: 753-760. Go to original source... Go to PubMed...
    23. Bahlmann F. Endothelial dysfunction: a new risk factor for cardiovascular disease in chronic kidney disease. 3rd Annual C.E.R.A. anaemia academy meeting, 6.8.10.2006, Budapešť. P 9.
    24. Crommelin DJA, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharmaceutics 2003; 266: 3-16. Go to original source... Go to PubMed...
    25. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature 2002; 1: 457-462. Go to original source... Go to PubMed...
    26. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004; 3: 43-47.
    27. Schmidt CA, Ramos AS, daSilva JEP, et al. Activity evaluation and characterization of recombinant human erythropoietin in pharmaceutical products. Arq Bras Endocrinol Metab 2003; 47: 183-189. Go to original source...
    28. Brinks V, Hawe A, Basmeleh AHH, et al. Quality of original and biosimilar epoetin products. Pharm Res 2010; published online 01 October 2010. Go to original source...
    29. Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology - a single-dialysis centre experience. Clin Nepheology 2011; 75: 59-62.
    30. Covic A, Cannat-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. NDT 2008; 23(12): 3731-3737. Go to original source... Go to PubMed...
    31. Minghetti P, Rocco P, Del Vecchio L, Locatelli F. Biosimilars and regulatory authorities. Nphron Clin Parct 2011; 117: c1-c7. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.